Stock Comparison
JNJ vs MO: Which Is the Better Pick in 2026?
A head-to-head comparison of Johnson & Johnson and Altria Group, Inc. covering yield, cost, risk, and income potential.
Updated October 16, 2026
How these figures are calculated: methodology.
Best for
- JNJInvestors who want direct ownership of the underlying business, with no fund wrapper or management fee.
- MOInvestors who want higher current income (5.91% vs 2.10% for JNJ).
Visual comparison
Key metrics
Projected income on $10K
Projections assume the current yield and share price remain constant. Actual results will vary.
Total returns
100% reinvested · ex-date convention. Period returns use this fixed assumption, independent of chart settings. YTD and 1Y are cumulative period returns; 3Y, 5Y, and 10Y are annualized. The shared Since-start window is annualized only when it covers at least one year.
JNJ has outpaced MO over the trailing twelve months, posting a 36.03% total return against 24.79%. The lead holds up over 10 years too: JNJ has compounded at 11.05% a year, against 9.11% for MO. Figures are total returns: price change plus every distribution reinvested.
| Symbol | YTD cumulative | 1Y cumulative | 3Y annualized | 5Y annualized | 10Y annualized | Since Nov 1984 | Volatility | Sharpe | Sortino | Max drawdown |
|---|---|---|---|---|---|---|---|---|---|---|
| JNJ | 25.49% | 36.03% | 20.89% | 12.74% | 11.05% | 14.40% | 18.4% | 0.81 | 1.16 | -14.4% |
| MO | 36.57% | 24.79% | 29.82% | 17.75% | 9.11% | 13.48% | 21.7% | 1.02 | 1.41 | -16.4% |
Total return with all distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date), split-adjusted, as of October 16, 2026. YTD and 1Y are cumulative period returns; 3Y, 5Y, and 10Y are annualized. The shared Since-start window is annualized only when it covers at least one year. “Since Nov 1984” measures every fund from November 5, 1984 — the start of shared available history — so all funds share one comparison window. Volatility is the annualized standard deviation of daily total returns over the trailing 3 years. Sharpe and Sortino divide the annualized return in excess of the risk-free rate by, respectively, that volatility and the downside deviation (both over the trailing 3 years) — higher is better. Max drawdown is the largest peak-to-trough total-return decline over the same window — shallower is better.
Side-by-side snapshot
| Metric |  JNJ |  MO |
|---|---|---|
| Full name | Johnson & Johnson | Altria Group, Inc. |
| Issuer | — | — |
| Last Close | $255.56 as of October 16, 2026 | $75.11 as of October 16, 2026 |
| Distribution rate | 2.10% | 5.91% |
| Trailing 12-month yield | 2.07% | 5.71% |
| Distribution Safety Score™ | 98 | 95 |
| Safety-Adjusted Yield | 2.06% | 5.61% |
| Expense ratio | — | — |
| AUM | — | — |
| Distribution frequency | Quarterly | Quarterly |
| Underlying index | — | — |
| Objective | Researches, develops, manufactures, and sells healthcare products including pharmaceuticals, medical devices, and consumer health products worldwide. | Manufactures and sells cigarettes, oral tobacco products, and wine in the United States through subsidiaries including Philip Morris USA and John Middleton. |
| Asset class | Equity | Equity |
| Inception date | N/A | N/A |
| Beta | 0.206 | 0.461 |
| Last dividend | $1.34 declared | $1.11 |
| Ex-dividend date | 11/24/2026 upcoming | 09/15/2026 |
Bottom lineChoose JNJ if you want direct ownership of the underlying business, with no fund wrapper or management fee. Choose MO if you want higher current income (5.91% vs 2.10% for JNJ).
Income calculator
See how much monthly income a hypothetical investment would generate in each stock at current yields.
Want to go deeper?
Add these stocks to a sample portfolio and forecast your dividend income over 5+ years — free to start, no credit card.
Quick verdict
JNJ (Johnson & Johnson) and MO (Altria Group, Inc.) are both quarterly-pay dividend-paying stocks, but they take different approaches.
MO offers the higher yield at 5.91% vs 2.10% for JNJ. A higher yield means more current income per dollar invested, though it may come with different risk characteristics.
Who should choose each?
Choose JNJ
Johnson & Johnson
- Want direct stock ownership — full upside and dividend growth potential, no fund wrapper or expense ratio.
- Prefer lower volatility — a beta of 0.2 vs 0.5 for MO.
Choose MO
Altria Group, Inc.
- Want higher current income — MO yields 5.91% vs 2.10% for JNJ.
- Want direct stock ownership — full upside and dividend growth potential, no fund wrapper or expense ratio.
Not sure? Use the income calculator and snapshot above to weigh these trade-offs against your own goals.
Still deciding? Track JNJ & MO for free
Create a free Dividend Vision account to keep them on a watchlist, get notified when they declare dividends, and see how much income they would add to your portfolio.
Deep dive
Yield & income
On a $10,000 investment, JNJ would generate roughly $52.50 cash per distribution, while MO would produce $147.75 cash per distribution, at current distribution rates. Both pay quarterly distributions.
Strategy & risk
JNJ is a stock built around pharmaceuticals & medical devices exposure, while MO is a stock built around tobacco exposure. Beta is 0.206 for JNJ and 0.461 for MO, making JNJ the less volatile of the two by this measure.
Security details
JNJ (Johnson & Johnson) is a stock. MO (Altria Group, Inc.) is a stock.
Enjoyed this page?
Do us a favor — if you found this comparison useful, please share it with a friend researching dividend investments.
Frequently asked questions
What is the current distribution rate for JNJ and MO?
JNJ currently distributes 2.10% and MO 5.91%, based on fund data updated October 2026. Distribution rate moves with both the payout and the share price, so check the as-of date before relying on either figure.
Is JNJ or MO better for dividend income?
It depends on your goals. MO currently offers the higher distribution yield, which means more income per dollar invested. However, a lower-yield fund may offer better total return or lower volatility. Consider your time horizon and risk tolerance.
What is the difference between JNJ and MO?
JNJ (Johnson & Johnson) is a stock built around pharmaceuticals & medical devices exposure, while MO (Altria Group, Inc.) is a stock built around tobacco exposure. They are issued by — and — respectively.
Can I hold both JNJ and MO?
Yes — nothing prevents holding both. Whether the combination actually diversifies depends on how much the underlying exposures overlap, which isn't fully measurable from the data on this page; review each security's holdings, sector, and strategy before treating them as complementary.
Is JNJ or MO safer?
By Dividend Vision's Distribution Safety Score — a rules-based 0–100 estimate of how resilient a distribution looks, where higher is safer — JNJ scores 98, MO scores 95, so JNJ's payout currently looks the more resilient of the two. JNJ has also shown lower price volatility (beta 0.21 vs 0.46 for MO). No score makes an investment risk-free — treat this as a screening signal, not a guarantee.
How much income does $10,000 in JNJ vs MO generate?
At current rates, $10,000 in JNJ would generate roughly $52.50 cash per distribution ($210.00 annually). The same in MO would produce about $147.75 cash per distribution ($591.00 annually).
Which has performed better historically, JNJ or MO?
JNJ has outpaced MO over the trailing twelve months, posting a 36.03% total return against 24.79%. The lead holds up over 10 years too: JNJ has compounded at 11.05% a year, against 9.11% for MO. Figures are total returns: price change plus every distribution reinvested. Past performance does not guarantee future results.
More comparisons to explore
Popular comparisons
JNJ vs MO — at a glance
Generated October 17, 2026.
Overview
Johnson & Johnson (JNJ) is a diversified healthcare company spanning pharmaceuticals, medical devices, and consumer health products. Altria Group (MO) manufactures and distributes cigarettes, oral tobacco, and wine in the United States. The fundamental distinction is their underlying businesses: JNJ operates in innovation-driven healthcare with global reach, while MO operates in mature, domestically focused tobacco and beverage markets with little product development risk.
How they differ
JNJ and MO occupy opposite ends of the dividend-yield and business-stability spectrum. JNJ's beta of 0.206 signals defensive characteristics—less than half MO's 0.461—suggesting JNJ's earnings move more gently with economic cycles, while MO, despite operating in a declining-volume industry, exhibits higher price sensitivity. JNJ was established 64 years, whereas MO's lineage 41 years reflects its restructuring from a broader tobacco conglomerate; the age difference underscores JNJ's longer track record of navigating multiple product cycles and regulatory environments.
Who each is best for
JNJ: Fits investors prioritizing steady capital preservation with modest but reliable income, particularly those seeking exposure to defensive sectors with below-market volatility and global diversification across healthcare innovation.
MO: Fits investors chasing high current yield who can tolerate regulatory, litigation, and volume-decline risks endemic to U.S. tobacco, and who view the business model as mature and cash-predictable rather than growth-oriented.
Key risks to know
- Regulatory and litigation exposure (MO): U.S. tobacco faces ongoing FDA regulation, potential excise tax increases, and class-action litigation. Unfavorable rulings or tax policy shifts could pressure both volumes and margins, directly threatening MO's payout sustainability.
- Declining smoking prevalence (MO): Cigarette consumption in the U.S. has trended downward for decades. MO's ability to maintain or grow cash flow depends largely on price increases and cost discipline rather than volume growth, leaving less room for error.
- Patent cliffs and R&D execution (JNJ): Healthcare companies depend on pipeline success and patent protection. Loss of exclusivity on key drugs or disappointing trial results could compress earnings growth and reduce reinvestment capacity, affecting long-term dividend sustainability.
- Cyclical earnings correlation (MO): Despite defensive branding, MO's 0.461 reflects sensitivity to economic cycles; consumer discretionary spending on premium tobacco products or wine can weaken during recessions, testing dividend coverage.
- Valuation and yield sustainability (MO): MO's 5.91% yield is notably elevated. Assessing whether it reflects genuine cash generation or rising payout ratios relative to earnings is essential; elevated yields can mask deteriorating coverage if earnings decline.
Bottom line
If you seek low volatility and modest, globally diversified income with upside from healthcare innovation, JNJ's lower yield and defensive beta appeal; if you prioritize current income and view U.S. tobacco as a stable, if slowly declining, cash machine, MO's higher payout fits that framework. Each carries distinct risks—JNJ faces pipeline and regulatory exposure, MO faces volume contraction and policy headwinds. Past performance does not predict future results.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
Learn the method
The metrics behind this comparison, explained in the Academy.
Still deciding? Compare them against your own portfolio
See how each stock fits alongside your real holdings — forecast future income, analyze overlap, and gauge risk. Start a free 7-day Dividend Vision trial and make the call with your full portfolio in view.
These comparisons follow the Dividend Vision methodology.